Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

pAR-B1(1986.1)
(Plasmid #78503)

Ordering

Item Catalog # Description Quantity Price (USD)
Plasmid 78503 Standard format: Plasmid sent in bacteria as agar stab 1 $85

This material is available to academics and nonprofits only.

Backbone

  • Vector backbone
    pAR
  • Backbone size w/o insert (bp) 3373
  • Total vector size (bp) 7469
  • Vector type
    Mammalian Expression, AAV

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    High Copy

Gene/Insert 1

  • Gene/Insert name
    AAV2 Rep
  • Species
    AAV2
  • Insert Size (bp)
    1863

Gene/Insert 2

  • Gene/Insert name
    AAV-B1 capsid
  • Species
    Chimeric capsid
  • Insert Size (bp)
    2214

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pAR-B1(1986.1) was a gift from Miguel Sena-Esteves (Addgene plasmid # 78503 ; http://n2t.net/addgene:78503 ; RRID:Addgene_78503)
  • For your References section:

    In vivo selection yields AAV-B1 capsid for CNS and muscle gene therapy. Choudhury SR, Fitzpatrick Z, Harris AF, Maitland SA, Ferreira JS, Zhang Y, Ma S, Sharma RB, Gray-Edwards HL, Johnson JA, Johnson AK, Alonso LC, Punzo C, Wagner KR, Maguire CA, Kotin RM, Martin DR, Sena-Esteves M. Mol Ther. 2016 Apr 27. doi: 10.1038/mt.2016.84. 10.1038/mt.2016.84 PubMed 27117222